Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stress Disorders, Post-Traumatic | 44 | 2021 | 4266 | 3.880 |
Why?
|
Pregnanolone | 12 | 2021 | 62 | 2.840 |
Why?
|
Neuropeptide Y | 8 | 2017 | 200 | 1.390 |
Why?
|
Progesterone | 7 | 2021 | 776 | 1.130 |
Why?
|
Tobacco Use Disorder | 4 | 2023 | 688 | 1.130 |
Why?
|
Neurotransmitter Agents | 4 | 2018 | 647 | 1.090 |
Why?
|
Dehydroepiandrosterone | 7 | 2018 | 252 | 1.000 |
Why?
|
Menstrual Cycle | 8 | 2021 | 551 | 1.000 |
Why?
|
Luteal Phase | 5 | 2021 | 147 | 0.990 |
Why?
|
Follicular Phase | 5 | 2021 | 153 | 0.990 |
Why?
|
Steroids | 2 | 2018 | 930 | 0.840 |
Why?
|
Exercise Therapy | 2 | 2020 | 906 | 0.780 |
Why?
|
Dissociative Disorders | 6 | 2016 | 231 | 0.750 |
Why?
|
Smoking Cessation | 3 | 2023 | 2071 | 0.710 |
Why?
|
Stress, Psychological | 13 | 2017 | 4245 | 0.680 |
Why?
|
Hydrocortisone | 13 | 2012 | 1826 | 0.640 |
Why?
|
Dehydroepiandrosterone Sulfate | 5 | 2018 | 238 | 0.610 |
Why?
|
Pituitary-Adrenal System | 5 | 2021 | 553 | 0.600 |
Why?
|
Hypothalamo-Hypophyseal System | 5 | 2021 | 703 | 0.570 |
Why?
|
Endophenotypes | 1 | 2018 | 250 | 0.560 |
Why?
|
Sweat Glands | 1 | 2016 | 31 | 0.560 |
Why?
|
Stress, Physiological | 8 | 2016 | 1403 | 0.550 |
Why?
|
Premenstrual Syndrome | 1 | 2016 | 109 | 0.540 |
Why?
|
Habituation, Psychophysiologic | 1 | 2016 | 154 | 0.530 |
Why?
|
Rape | 1 | 2016 | 133 | 0.520 |
Why?
|
Body Temperature Regulation | 1 | 2016 | 252 | 0.510 |
Why?
|
Neuroanatomy | 1 | 2015 | 66 | 0.500 |
Why?
|
Galvanic Skin Response | 1 | 2016 | 349 | 0.480 |
Why?
|
Hormones | 1 | 2018 | 889 | 0.480 |
Why?
|
Neurobiology | 1 | 2015 | 121 | 0.480 |
Why?
|
Panic Disorder | 2 | 2016 | 616 | 0.470 |
Why?
|
Sympathetic Nervous System | 1 | 2016 | 514 | 0.450 |
Why?
|
Adult Survivors of Child Abuse | 1 | 2016 | 260 | 0.430 |
Why?
|
Neuropeptides | 1 | 2018 | 942 | 0.430 |
Why?
|
Phobic Disorders | 1 | 2015 | 439 | 0.420 |
Why?
|
5-alpha-Dihydroprogesterone | 3 | 2018 | 5 | 0.410 |
Why?
|
Irritable Bowel Syndrome | 1 | 2017 | 445 | 0.390 |
Why?
|
Combat Disorders | 3 | 2017 | 302 | 0.370 |
Why?
|
Fluoxetine | 3 | 2012 | 749 | 0.360 |
Why?
|
Yohimbine | 3 | 2003 | 62 | 0.360 |
Why?
|
Adrenergic alpha-Antagonists | 2 | 2000 | 174 | 0.330 |
Why?
|
Hydroxysteroid Dehydrogenases | 2 | 2018 | 29 | 0.330 |
Why?
|
Fear | 9 | 2021 | 1440 | 0.330 |
Why?
|
Receptors, GABA-A | 3 | 2018 | 627 | 0.330 |
Why?
|
Disability Evaluation | 1 | 2016 | 1827 | 0.320 |
Why?
|
Veterans | 9 | 2019 | 2519 | 0.280 |
Why?
|
Sex Characteristics | 1 | 2015 | 2585 | 0.260 |
Why?
|
Pain | 1 | 2020 | 4986 | 0.260 |
Why?
|
Anxiety | 4 | 2021 | 4297 | 0.250 |
Why?
|
Comorbidity | 9 | 2018 | 10388 | 0.250 |
Why?
|
Depressive Disorder | 3 | 2016 | 3748 | 0.240 |
Why?
|
Smoking | 3 | 2023 | 8987 | 0.240 |
Why?
|
Adult | 42 | 2021 | 214055 | 0.220 |
Why?
|
Health Status | 1 | 2016 | 4034 | 0.220 |
Why?
|
Adrenal Glands | 1 | 2004 | 546 | 0.200 |
Why?
|
Extinction, Psychological | 2 | 2016 | 376 | 0.200 |
Why?
|
Dentate Gyrus | 1 | 2002 | 160 | 0.200 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2006 | 632 | 0.190 |
Why?
|
Female | 39 | 2021 | 380194 | 0.190 |
Why?
|
Affect | 3 | 2013 | 1476 | 0.190 |
Why?
|
Humans | 61 | 2023 | 744343 | 0.180 |
Why?
|
United States Department of Veterans Affairs | 2 | 2015 | 875 | 0.180 |
Why?
|
Exercise | 1 | 2016 | 5615 | 0.170 |
Why?
|
Cholestenone 5 alpha-Reductase | 1 | 2018 | 21 | 0.170 |
Why?
|
Tourette Syndrome | 3 | 1997 | 379 | 0.170 |
Why?
|
Psychiatric Status Rating Scales | 9 | 2017 | 6038 | 0.170 |
Why?
|
Receptors, Adrenergic, alpha-2 | 1 | 1998 | 64 | 0.160 |
Why?
|
GABA Agents | 1 | 2018 | 42 | 0.160 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 2 | 2021 | 895 | 0.160 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2002 | 604 | 0.160 |
Why?
|
Male | 37 | 2021 | 350118 | 0.160 |
Why?
|
Androstane-3,17-diol | 1 | 2017 | 19 | 0.160 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2018 | 361 | 0.160 |
Why?
|
Glucocorticoids | 3 | 2017 | 2107 | 0.150 |
Why?
|
Mood Disorders | 1 | 2004 | 1106 | 0.150 |
Why?
|
Premenopause | 1 | 2001 | 1033 | 0.150 |
Why?
|
Cues | 1 | 2002 | 873 | 0.150 |
Why?
|
Military Personnel | 6 | 2019 | 1133 | 0.140 |
Why?
|
Midwestern United States | 1 | 2016 | 70 | 0.140 |
Why?
|
Receptors, GABA | 1 | 2018 | 288 | 0.140 |
Why?
|
Pilot Projects | 3 | 2018 | 8324 | 0.130 |
Why?
|
Substance Abuse Detection | 1 | 2018 | 283 | 0.130 |
Why?
|
8-Hydroxy-2-(di-n-propylamino)tetralin | 1 | 1994 | 32 | 0.130 |
Why?
|
Young Adult | 10 | 2021 | 56430 | 0.130 |
Why?
|
Infrared Rays | 1 | 2016 | 249 | 0.130 |
Why?
|
Ghrelin | 1 | 2017 | 266 | 0.130 |
Why?
|
Down-Regulation | 1 | 2002 | 3002 | 0.130 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2021 | 1121 | 0.120 |
Why?
|
Affective Symptoms | 1 | 2017 | 407 | 0.120 |
Why?
|
Tryptophan | 1 | 1997 | 478 | 0.120 |
Why?
|
Afghan Campaign 2001- | 1 | 2015 | 272 | 0.120 |
Why?
|
Brain Injuries | 2 | 2019 | 2025 | 0.120 |
Why?
|
Thinness | 1 | 2017 | 480 | 0.120 |
Why?
|
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2014 | 88 | 0.120 |
Why?
|
Serotonin Receptor Agonists | 1 | 1994 | 152 | 0.120 |
Why?
|
Gastric Mucosa | 1 | 2017 | 599 | 0.120 |
Why?
|
Middle Aged | 17 | 2021 | 213383 | 0.110 |
Why?
|
Cross-Over Studies | 2 | 2017 | 2029 | 0.110 |
Why?
|
Constipation | 1 | 2017 | 546 | 0.100 |
Why?
|
Carbon Dioxide | 1 | 2016 | 1150 | 0.100 |
Why?
|
Depression | 5 | 2017 | 7766 | 0.100 |
Why?
|
Pain Threshold | 1 | 2016 | 584 | 0.100 |
Why?
|
Menopause | 1 | 2019 | 1626 | 0.100 |
Why?
|
Saliva | 5 | 2012 | 809 | 0.100 |
Why?
|
Potassium Channels | 1 | 2014 | 563 | 0.100 |
Why?
|
Case-Control Studies | 4 | 2016 | 21746 | 0.100 |
Why?
|
Prefrontal Cortex | 4 | 1999 | 2147 | 0.100 |
Why?
|
Obsessive-Compulsive Disorder | 2 | 1997 | 1444 | 0.100 |
Why?
|
Valproic Acid | 1 | 2013 | 445 | 0.090 |
Why?
|
Severity of Illness Index | 7 | 2018 | 15540 | 0.090 |
Why?
|
Conditioning, Classical | 1 | 2013 | 366 | 0.090 |
Why?
|
Police | 1 | 2012 | 149 | 0.090 |
Why?
|
Diarrhea | 1 | 2017 | 1348 | 0.090 |
Why?
|
Double-Blind Method | 5 | 2017 | 12026 | 0.090 |
Why?
|
Estradiol | 1 | 2017 | 2020 | 0.090 |
Why?
|
Behavior, Animal | 3 | 2012 | 1881 | 0.080 |
Why?
|
tau Proteins | 1 | 2019 | 1868 | 0.080 |
Why?
|
Anorexia Nervosa | 1 | 2017 | 1286 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2018 | 5078 | 0.080 |
Why?
|
Disease Models, Animal | 3 | 2012 | 18029 | 0.080 |
Why?
|
Animals | 14 | 2017 | 168757 | 0.080 |
Why?
|
Brain | 4 | 2019 | 26385 | 0.080 |
Why?
|
Up-Regulation | 2 | 2012 | 4217 | 0.080 |
Why?
|
Exercise Test | 1 | 2016 | 2074 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 789 | 0.080 |
Why?
|
Guanfacine | 1 | 2008 | 51 | 0.080 |
Why?
|
Brain Concussion | 1 | 2019 | 1320 | 0.080 |
Why?
|
Adrenergic alpha-2 Receptor Agonists | 1 | 2008 | 87 | 0.070 |
Why?
|
RNA, Messenger | 1 | 2002 | 13033 | 0.070 |
Why?
|
Psychotherapy | 1 | 2016 | 1643 | 0.070 |
Why?
|
Self Report | 1 | 2018 | 3558 | 0.070 |
Why?
|
Overweight | 1 | 2017 | 2371 | 0.070 |
Why?
|
Pituitary-Adrenal Function Tests | 2 | 2003 | 31 | 0.070 |
Why?
|
Substance-Related Disorders | 2 | 2018 | 4258 | 0.070 |
Why?
|
Testosterone | 2 | 2017 | 2420 | 0.060 |
Why?
|
Cosyntropin | 1 | 2004 | 33 | 0.060 |
Why?
|
Executive Function | 1 | 2013 | 1364 | 0.060 |
Why?
|
Depressive Disorder, Major | 2 | 2018 | 4644 | 0.060 |
Why?
|
Antidepressive Agents | 1 | 2016 | 2838 | 0.060 |
Why?
|
Urban Population | 2 | 2003 | 2021 | 0.060 |
Why?
|
Dietary Carbohydrates | 1 | 2009 | 906 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 1312 | 0.060 |
Why?
|
Nicotinic Agonists | 1 | 2006 | 271 | 0.060 |
Why?
|
Corticotropin-Releasing Hormone | 2 | 2003 | 369 | 0.060 |
Why?
|
Adolescent | 8 | 2018 | 85781 | 0.060 |
Why?
|
Emotions | 2 | 2012 | 2661 | 0.060 |
Why?
|
Adrenocorticotropic Hormone | 2 | 2003 | 648 | 0.060 |
Why?
|
Norepinephrine | 3 | 2002 | 909 | 0.060 |
Why?
|
Serotonin | 3 | 1999 | 1017 | 0.060 |
Why?
|
Catecholamines | 2 | 2001 | 387 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2019 | 6234 | 0.050 |
Why?
|
20-alpha-Dihydroprogesterone | 1 | 2001 | 2 | 0.050 |
Why?
|
Analysis of Variance | 3 | 2006 | 6365 | 0.050 |
Why?
|
Biomedical Research | 1 | 2018 | 3309 | 0.050 |
Why?
|
Acoustic Stimulation | 2 | 2005 | 1216 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 5 | 2002 | 8301 | 0.050 |
Why?
|
Behavior | 1 | 2004 | 561 | 0.050 |
Why?
|
Teaching | 1 | 2009 | 1174 | 0.050 |
Why?
|
Cognition Disorders | 2 | 2009 | 4043 | 0.050 |
Why?
|
Task Performance and Analysis | 3 | 2013 | 780 | 0.050 |
Why?
|
Avoidance Learning | 1 | 2002 | 233 | 0.050 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4462 | 0.050 |
Why?
|
Nicotine | 1 | 2006 | 681 | 0.050 |
Why?
|
Child Abuse, Sexual | 1 | 2003 | 383 | 0.050 |
Why?
|
Methoxyhydroxyphenylglycol | 1 | 2000 | 93 | 0.050 |
Why?
|
Social Behavior Disorders | 1 | 2000 | 97 | 0.050 |
Why?
|
Arousal | 2 | 2003 | 1165 | 0.040 |
Why?
|
Antipsychotic Agents | 1 | 2013 | 3057 | 0.040 |
Why?
|
Survival | 1 | 2000 | 163 | 0.040 |
Why?
|
Dopamine | 2 | 1999 | 1591 | 0.040 |
Why?
|
Afghanistan | 1 | 2019 | 81 | 0.040 |
Why?
|
Reference Values | 1 | 2006 | 4982 | 0.040 |
Why?
|
Iraq | 1 | 2019 | 92 | 0.040 |
Why?
|
Social Isolation | 1 | 2001 | 365 | 0.040 |
Why?
|
Cross-Sectional Studies | 2 | 2017 | 25043 | 0.040 |
Why?
|
Fluvoxamine | 1 | 1998 | 74 | 0.040 |
Why?
|
Repression-Sensitization | 1 | 1997 | 1 | 0.040 |
Why?
|
Life Change Events | 3 | 2012 | 938 | 0.040 |
Why?
|
Estrogens | 1 | 2004 | 1566 | 0.040 |
Why?
|
Electric Stimulation | 1 | 2002 | 1767 | 0.040 |
Why?
|
Chromatography, Liquid | 1 | 2021 | 976 | 0.040 |
Why?
|
Prospective Studies | 2 | 2020 | 53288 | 0.040 |
Why?
|
Mice | 4 | 2013 | 81183 | 0.040 |
Why?
|
Breath Tests | 1 | 2018 | 280 | 0.040 |
Why?
|
Biogenic Monoamines | 1 | 1996 | 50 | 0.040 |
Why?
|
Rats | 5 | 2002 | 24260 | 0.040 |
Why?
|
Dexamethasone | 1 | 2003 | 1951 | 0.030 |
Why?
|
Aged | 7 | 2019 | 163280 | 0.030 |
Why?
|
Urinalysis | 1 | 2018 | 369 | 0.030 |
Why?
|
Heart Rate | 2 | 2012 | 4091 | 0.030 |
Why?
|
Blast Injuries | 1 | 2019 | 302 | 0.030 |
Why?
|
Genome-Wide Association Study | 1 | 2014 | 12261 | 0.030 |
Why?
|
Sertraline | 1 | 2016 | 206 | 0.030 |
Why?
|
Tandem Mass Spectrometry | 1 | 2021 | 1157 | 0.030 |
Why?
|
Telephone | 1 | 2018 | 617 | 0.030 |
Why?
|
United States | 4 | 2015 | 69872 | 0.030 |
Why?
|
Recurrence | 1 | 2006 | 8340 | 0.030 |
Why?
|
Violence | 1 | 2000 | 909 | 0.030 |
Why?
|
Pyrrolidinones | 1 | 1994 | 117 | 0.030 |
Why?
|
Models, Biological | 1 | 2010 | 9583 | 0.030 |
Why?
|
Neuronal Plasticity | 1 | 2002 | 1422 | 0.030 |
Why?
|
Butyric Acid | 1 | 2013 | 55 | 0.030 |
Why?
|
Dopamine Antagonists | 1 | 1994 | 296 | 0.030 |
Why?
|
Treatment Outcome | 2 | 2017 | 63114 | 0.030 |
Why?
|
Neurologic Examination | 1 | 1997 | 930 | 0.030 |
Why?
|
Nerve Degeneration | 1 | 1997 | 748 | 0.030 |
Why?
|
Adaptation, Psychological | 1 | 2003 | 2576 | 0.030 |
Why?
|
Hippocampus | 2 | 2012 | 3675 | 0.030 |
Why?
|
Anti-Anxiety Agents | 1 | 1994 | 390 | 0.030 |
Why?
|
Off-Label Use | 1 | 2013 | 169 | 0.030 |
Why?
|
Circadian Rhythm | 1 | 2003 | 2624 | 0.030 |
Why?
|
Neurons | 2 | 2002 | 9338 | 0.020 |
Why?
|
Primary Health Care | 2 | 2014 | 4558 | 0.020 |
Why?
|
Wounds and Injuries | 1 | 2003 | 2400 | 0.020 |
Why?
|
Desipramine | 1 | 1991 | 184 | 0.020 |
Why?
|
Risk Factors | 4 | 2012 | 72290 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 911 | 0.020 |
Why?
|
Research Design | 1 | 2006 | 5987 | 0.020 |
Why?
|
Neuropsychological Tests | 2 | 2019 | 6993 | 0.020 |
Why?
|
Death, Sudden | 1 | 1991 | 302 | 0.020 |
Why?
|
Amygdala | 1 | 1996 | 1315 | 0.020 |
Why?
|
Psychometrics | 2 | 2012 | 3002 | 0.020 |
Why?
|
Electromyography | 1 | 2012 | 1379 | 0.020 |
Why?
|
Psychotic Disorders | 1 | 2001 | 3046 | 0.020 |
Why?
|
Chronic Disease | 1 | 2001 | 9146 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2488 | 0.020 |
Why?
|
Aging | 1 | 2004 | 8664 | 0.020 |
Why?
|
Placebo Effect | 1 | 2009 | 502 | 0.020 |
Why?
|
Time Factors | 3 | 2013 | 40075 | 0.020 |
Why?
|
Blinking | 1 | 2005 | 138 | 0.020 |
Why?
|
Corticosterone | 2 | 1996 | 310 | 0.020 |
Why?
|
Blood Pressure | 1 | 2000 | 8554 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2016 | 8642 | 0.010 |
Why?
|
Neurosecretory Systems | 1 | 2003 | 231 | 0.010 |
Why?
|
Prevalence | 2 | 2014 | 15226 | 0.010 |
Why?
|
Problem Solving | 1 | 2004 | 440 | 0.010 |
Why?
|
Cerebrovascular Circulation | 1 | 1992 | 2731 | 0.010 |
Why?
|
Boston | 1 | 2014 | 9313 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 2012 | 2690 | 0.010 |
Why?
|
Personality Inventory | 1 | 2003 | 1030 | 0.010 |
Why?
|
Adrenergic Uptake Inhibitors | 1 | 2001 | 189 | 0.010 |
Why?
|
Mental Health | 1 | 2014 | 3019 | 0.010 |
Why?
|
Connecticut | 1 | 2000 | 366 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 12720 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2013 | 7785 | 0.010 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 1999 | 158 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9959 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2021 | 77449 | 0.010 |
Why?
|
Placebos | 1 | 2003 | 1676 | 0.010 |
Why?
|
Adrenergic alpha-Agonists | 1 | 1999 | 177 | 0.010 |
Why?
|
Epinephrine | 1 | 2002 | 792 | 0.010 |
Why?
|
Oxidopamine | 1 | 1999 | 169 | 0.010 |
Why?
|
Poverty Areas | 1 | 2000 | 275 | 0.010 |
Why?
|
Adrenergic Agents | 1 | 1999 | 70 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 35421 | 0.010 |
Why?
|
Child | 6 | 2005 | 77709 | 0.010 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 1999 | 434 | 0.010 |
Why?
|
Stereoisomerism | 1 | 1998 | 624 | 0.010 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 1 | 1996 | 64 | 0.010 |
Why?
|
Akathisia, Drug-Induced | 1 | 1997 | 67 | 0.010 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 1 | 2003 | 1953 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2012 | 13989 | 0.010 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 1991 | 3658 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2014 | 15519 | 0.010 |
Why?
|
Regression Analysis | 1 | 2004 | 6459 | 0.010 |
Why?
|
Acute Disease | 1 | 2004 | 7149 | 0.010 |
Why?
|
Nucleus Accumbens | 1 | 1994 | 366 | 0.010 |
Why?
|
Adolescent Behavior | 1 | 2000 | 1151 | 0.010 |
Why?
|
Cognition | 1 | 2009 | 6770 | 0.010 |
Why?
|
Glycine | 1 | 1994 | 671 | 0.010 |
Why?
|
Recovery of Function | 1 | 2001 | 2925 | 0.010 |
Why?
|
Memory | 1 | 1999 | 2174 | 0.010 |
Why?
|
Ventricular Fibrillation | 1 | 1991 | 538 | 0.000 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 1992 | 1107 | 0.000 |
Why?
|
Heart Arrest | 1 | 1991 | 1470 | 0.000 |
Why?
|